Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal
Open Access

The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight

Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe and Yusuke Moritoh
Journal of Pharmacology and Experimental Therapeutics October 2020, 375 (1) 21-27; DOI: https://doi.org/10.1124/jpet.120.000046
Mitsugi Ookawara
SCOHIA PHARMA, Inc., Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keisuke Matsuda
SCOHIA PHARMA, Inc., Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masanori Watanabe
SCOHIA PHARMA, Inc., Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yusuke Moritoh
SCOHIA PHARMA, Inc., Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yusuke Moritoh
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 375 no. 1 21-27
DOI 
https://doi.org/10.1124/jpet.120.000046
PubMed 
32719069

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received April 11, 2020
  • Accepted July 21, 2020
  • Published online September 12, 2020.

Article Versions

  • Earlier version (July 27, 2020 - 08:39).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2020 The Author(s) This is an open access article distributed under the CC BY Attribution 4.0 International license.

Author Information

  1. Mitsugi Ookawara,
  2. Keisuke Matsuda,
  3. Masanori Watanabe, and
  4. Yusuke Moritoh
  1. SCOHIA PHARMA, Inc., Kanagawa, Japan
  1. Address correspondence to:
    Yusuke Moritoh, Research and Development Division, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. E-mail: yusuke.moritoh{at}scohia.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: July 2020 to February 2023

AbstractFullPdf
Jul 20201820164
Aug 20202260118
Sep 202028410385
Oct 20202119290
Nov 2020185942
Dec 2020256561
Jan 2021217553
Feb 2021227545
Mar 2021244635
Apr 2021133435
May 2021325140
Jun 2021294635
Jul 2021303630
Aug 2021373929
Sep 202144337
Oct 202174151
Nov 2021324034
Dec 202153831
Jan 2022133253
Feb 2022103328
Mar 202204625
Apr 202253844
May 202295334
Jun 202233321
Jul 202293613
Aug 2022136046
Sep 202255650
Oct 202282931
Nov 202243227
Dec 2022134832
Jan 202384827
Feb 2023061

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 375 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 375, Issue 1
1 Oct 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

GPR40 Full Agonist for Nonalcoholic Fatty Liver Disease

Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe and Yusuke Moritoh
Journal of Pharmacology and Experimental Therapeutics October 1, 2020, 375 (1) 21-27; DOI: https://doi.org/10.1124/jpet.120.000046

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

GPR40 Full Agonist for Nonalcoholic Fatty Liver Disease

Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe and Yusuke Moritoh
Journal of Pharmacology and Experimental Therapeutics October 1, 2020, 375 (1) 21-27; DOI: https://doi.org/10.1124/jpet.120.000046
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A Novel Long-Acting GLP-2, HM15912, for Short Bowel Syndrome
  • H2S Overproduction and Colonic Hypomotility in DM
  • MIP3a in Progressive Renal Injury Associated With Obesity
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics